Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy

Trial Profile

Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Anlotinib (Primary) ; Irinotecan (Primary)
  • Indications Ewing's sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top